基于丙型肝炎病毒学状态的机器学习模型用于肝硬化患者肝细胞癌个体化监测
基于法国ANRS CO12 CirVir队列中836例代偿期活检证实的HCV相关肝硬化患者,按是否获得持续病毒学应答(SVR)分别构建Fine-Gray回归、单决策树和随机生存森林模型预测HCC发生,并在ANRS CO22 Hepather队列(n=668)外部验证。SVR前后风险因素不同,随机生存森林外部验证C-index在SVR前/后分别为0.71/0.70。
要点
- HCV相关肝硬化患者SVR前后HCC预测因素不同,需按病毒学状态分层评估。
- 随机生存森林模型外部验证C-index在SVR前为0.71、SVR后为0.70,优于Fine-Gray回归和单决策树。
- 机器学习可揭示预测因素间复杂交互,有望用于制定更具成本效果的个体化监测方案。
核心结论
- HCV相关肝硬化患者肝癌发生的风险因素因SVR状态而异,机器学习算法可通过揭示预测因素间复杂交互来改进HCC风险评估。
研究设计与样本
- 研究纳入法国ANRS CO12 CirVir队列中836例代偿期活检证实的HCV相关肝硬化患者,均接受每半年一次HCC监测。
- 构建三种HCC发生预测模型:Fine-Gray回归作为基准、单决策树和竞争风险随机生存森林。
- 模型性能通过C-index评估,并在ANRS CO22 Hepather队列(n=668,2012年8月至2014年1月入组)外部验证。
主要发现
- 836例患者中156例(19%)发生HCC,434例(52%)获得SVR,中位随访63个月。
- Fine-Gray回归在SVR前识别6个独立预测因素(既往过量饮酒、基因1型、AFP和GGT升高、血小板计数和白蛋白降低),SVR后识别3个(AST升高、血小板计数降低、凝血酶原时间缩短)。
- 决策树分析确认上述关联但揭示更复杂交互,形成8个癌症风险及预测因素各异的患者组,取决于SVR是否达成。
- 随机生存森林中最重要的预测因素随SVR状态变化:非SVR为血小板计数、GGT、AFP和白蛋白;SVR为凝血酶原时间、ALT、年龄和血小板计数。
关键数值与推荐
- Fine-Gray回归SVR前HCC独立预测因素:既往过量饮酒、基因1型、AFP升高、GGT升高、血小板计数降低、白蛋白降低。
- Fine-Gray回归SVR后HCC独立预测因素:AST升高、血小板计数降低、凝血酶原时间缩短。
临床怎么用
- 作者认为机器学习算法可改进个体化风险预测,此类方法可用于制定更具成本效果的定制监测方案。
- 原文指出使用MRI等更先进影像技术细化监测周期和方式可能仅对HCC发生率最高的患者具有成本效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Refining hepatocellular carcinoma (HCC) surveillance programs requires improved individual risk prediction. Thus, we aimed to develop algorithms based on machine learning approaches to predict the risk of HCC more accurately in patients with HCV-related cirrhosis, according to their virological status. METHODS: Patients with compensated biopsy-proven HCV-related cirrhosis from the French ANRS CO12 CirVir cohort were included in a semi-annual HCC surveillance program. Three prognostic models for HCC occurrence were built, using (i) Fine-Gray regression as a benchmark, (ii) single decision tree (DT), and (iii) random survival forest for competing risks survival (RSF). Model performance was evaluated from C-indexes validated externally in the ANRS CO22 Hepather cohort (n = 668 enrolled between 08/2012-01/2014). RESULTS: Out of 836 patients analyzed, 156 (19%) developed HCC and 434 (52%) achieved sustained virological response (SVR) (median follow-up 63 months). Fine-Gray regression models identified 6 independent predictors of HCC occurrence in patients before SVR (past excessive alcohol intake, genotype 1, elevated AFP and GGT, low platelet count and albuminemia) and 3 in patients after SVR (elevated AST, low platelet count and shorter prothrombin time). DT analysis confirmed these associations but revealed more complex interactions, yielding 8 patient groups with varying cancer risks and predictors depending on SVR achievement. On RSF analysis, the most important predictors of HCC varied by SVR status (non-SVR: platelet count, GGT, AFP and albuminemia; SVR: prothrombin time, ALT, age and platelet count). Externally validated C-indexes before/after SVR were 0.64/0.64 [Fine-Gray], 0.60/62 [DT] and 0.71/0.70 [RSF]. CONCLUSIONS: Risk factors for hepatocarcinogenesis differ according to SVR status. Machine learning algorithms can refine HCC risk assessment by revealing complex interactions between cancer predictors. Such approaches could be used to develop more cost-effective tailored surveillance programs. LAY SUMMARY: Patients with HCV-related cirrhosis must be included in liver cancer surveillance programs, which rely on ultrasound examination every 6 months. Hepatocellular carcinoma (HCC) screening is hampered by sensitivity issues, leading to late cancer diagnoses in a substantial number of patients. Refining surveillance periodicity and modality using more sophisticated imaging techniques such as MRI may only be cost-effective in patients with the highest HCC incidence. Herein, we demonstrate how machine learning algorithms (i.e. data-driven mathematical models to make predictions or decisions), can refine individualized risk prediction.
引用
- Audureau E, Carrat F, Layese R, et al. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status. J Hepatol. 2020. PMID: 32615276. doi:10.1016/j.jhep.2020.05.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。